Success Metrics

Active Trials

2(40%)

Phase Distribution

Ph not_applicable

60%

Ph phase_1

40%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

2(40.0%)

N/ANon-phased studies

3(60.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Other(2)

Detailed Status

unknown2

Recruiting2

Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 1

Trials by Phase

Phase 12 (40.0%)

N/A3 (60.0%)

Trials by Status

unknown240%

recruiting240%

not_yet_recruiting120%

Recent Activity

2 active trials

Showing 5 of 5

recruitingphase_1

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

NCT06789172

recruitingphase_1

Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RZ-629 in Healthy Subjects and T2D

NCT06829563

not_yet_recruitingnot_applicable

Clinical Trials (5)

Showing 5 of 5 trials

NCT06789172Phase 1

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

Recruiting

NCT06829563Phase 1

Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RZ-629 in Healthy Subjects and T2D

Recruiting

NCT06550466Not Applicable

The Effect of Pre-exercise Feeding on Bone Turnover Biomarkers

Not Yet Recruiting

NCT06000605Not Applicable

Brain Substrate Switch to Ketones and Lactate

Unknown

NCT05422300Not Applicable

A 'Non-Invasive' Breath Test to Determine Anabolic Sensitivity in Females

Unknown

All 5 trials loaded

Drug Details

Intervention Type: OTHER
Total Trials: 5